Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Vincerx Pharma, Inc. (VINC : NSDQ)

• Company Description    Vincerx Pharma Inc. is a biopharmaceutical company. It focuses on unmet medical needs of patients with cancer through paradigm-shifting therapeutics. Vincerx Pharma Inc. is based in PALO ALTO, Calif. Number of Employees: 56

• Price / Volume Information    Yesterday's Closing Price: $1.77 Daily Weekly Monthly 20 Day Moving Average: 78,261 shares Shares Outstanding: 21.06 (millions) Market Capitalization: $37.27 (millions) Beta: 1.62 52 Week High: $18.43 52 Week Low: $1.67 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -31.40% -22.73% 12 Week -68.22% -65.06% Year To Date -82.63% -78.78%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 260 SHERIDAN AVENUE SUITE 400 - PALO ALTO,CA 94306 USA ph: 650-800-6676 fax: - None http://www.vincerx.com

• General Corporate Information    Officers Ahmed M. Hamdy - Chief Executive Officer and Chairman Alexander A. Seelenberger - Chief Financial Officer Laura I. Bushnell - Director Brian J. Druker - Director John H. Lee - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 92731L106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 21.06 Most Recent Split Date: (:1) Beta: 1.62 Market Capitalization: $37.27 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.07 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.17 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.42 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -71.74% vs. Previous Quarter: 7.06% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -59.83 12/31/21 - -58.98 09/30/21 - -76.19 ROA 03/31/22 - -48.95 12/31/21 - -44.37 09/30/21 - -49.75 Current Ratio 03/31/22 - 8.51 12/31/21 - 8.04 09/30/21 - 4.90 Quick Ratio 03/31/22 - 8.51 12/31/21 - 8.04 09/30/21 - 4.90 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 4.23 12/31/21 - 4.76 09/30/21 - 4.79 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©